David Warshawsky, PhD

Founder, Chairman of the Board of Directors 

David is an entrepreneur with more than 20 years of international experience in research, product development, management & business development in life sciences. David strongly believes in deploying multidimensional approaches to tackle big problems, and in utilizing data mining and bioinformatics, molecular biology and innovative drug discovery and clinical development approaches. 

David was founder & CEO of LifeMap Sciences, Inc.; founder & CEO of XenneX, Inc.; and founder & CEO of Avraham Pharmaceuticals, Ltd.; and founder of Varinel, Inc.; VP, Business Development at Paramount Biosciences; and Director of Business Development World Wide at Compugen Inc. From 1996-1999 he was a research fellow at Harvard and Harvard Medical School. He earned his Ph.D. in Molecular Biology in 1995 from the University of Illinois at Chicago and B.Sc. in Biology from Tel Aviv University in 1991. 


Rick Lampe, MSc 

Co-Founder, CEO, Product Development & Regulatory, Director 

Rick brings a broad understanding of pharmaceutical industry based upon 30 years of experience in research and development functions. Rick brings a proven ability to resolve issues, lead teams and deliver outcomes in compliance with government and industry regulations. 

Rick's experience includes a balanced portfolio of critical pharmaceutical development skills and experiences developed within multiple environments, including Avraham Pharmaceuticals, Ltd., YM Biosciences, Inc., Eximias Pharmaceuticals, Corp., and New River Pharmaceuticals, Inc., Fifteen years in various research, regulatory and project management positions at AstraZeneca Pharmaceuticals, and 8 years as staff scientist at E.I. Du Pont de Nemours & Co. Rick earned his M.S. in Biochemistry, University of Kansas, Lawrence, KS, 1981 and his B.Sc. in Neuropsychology, University of Virginia, Charlottesville, VA, 1975.  


 Robert E. Hurst, PhD 

Co-Founder, Chief Scientific Officer, Director 

 Bob brings broad experience in novel therapeutic approaches to prevention and treatment of metastasis, biomarkers for diagnosis and prognosis of malignancy and the carcinogenic process. Bob is Professor Emeritus, Department of Urology, University of Oklahoma Health Sciences Center. He was also a founder of DormaTarg.   

Bob has published over 150 peer reviewed papers and is listed as an inventor on 11 patents to date. In 2009 he was named "Innovator of the Year" by the "Oklahoma Journal Record", the State's business newspaper. Bob is a Fellow of the American Association for the Advancement of Science. Bob earned his Bachelor's of Science from Auburn University and his Ph.D. in biochemistry from Florida State University.   


 Raphael Nir, PhD 

Co-Founder, Head of Preclinical Discovery  

Raphael is a scientist, entrepreneur and angel investor with 27 years of biotechnology experience spanning preclinical research, drug discovery, cell-based assays, process development and recombinant cytokines production. He is founder and owner of SBH Sciences, which he built from the ground up to become a leading supplier of recombinant cytokines and a preferred discovery research organization that has assisted more than 180 biotechnology companies since 1997. 

Raphael also co-founded the biotechnology companies Karyopharm Therapeutics (NASDAQ: KPTI), Galectin Sciences and Alma Bio Therapeutics, is co-founder of SBH Diagnostics, and co-founder and partner at Sky Ventures, Woodland Biosciences and ABI-LAB. 

Raphael earned his Ph.D. in biotechnology his M.S. in biochemistry, and his B.S. in chemistry from Tel-Aviv University and his M.S. in engineering management from New Jersey Institute of Technology. He was a postdoctoral researcher at Schering Plough Research Institute where he later became a Senior Scientist/Associate Principal Scientist and developed innovative cell culture processes and solutions related to biological production.  


 Chand Khanna, DVM, PhD, DACVIM (Onc) Director 

 Dr. Khanna  is currently the Chief Science Officer of Ethos Veterinary Health and President of the non-profit incubator of scientific innovation, Ethos Discovery (501c.3.). In these roles Dr. Khanna seeks to improve outcomes for human and pet patients with complex medical problems through the development of novel therapeutics and diagnostics. 

Dr. Khanna was the longtime Head of the NCI Pediatric Oncology Branch’s Tumor and Metastasis Biology Section, and the Founding Director of the Center for Cancer Research, Comparative Oncology Program. His research interests and responsibilities focused on the problem of cancer metastasis and the discovery of new options to treat patients with metastasis. Dr. Khanna has over 100 publications in the area of cancer biology and therapy. 


Lee Helman, MD


Dr. Helman is Section Head of Basic and Translational Research within the Children's Center for Cancer and Blood Diseases and Director of the Cancer and Blood Diseases Research Program of the Saban Research Institute of Children's Hospital Los Angeles. He is also Professor of Pediatrics in the Keck School of Medicine of USC. Dr. Helman has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. He has also trained many investigators in the field of pediatric sarcomas. One current area of active research at Children’s Hospital Los Angeles focuses on using full genomic classification of osteosarcoma tumors to improve therapy, as well as testing novel therapeutic drugs and drug combinations in patients with osteosarcoma. 

Dr. Helman received his medical degree from the University of Maryland School of Medicine magna cum laude in 1980 and was elected to Alpha Omega Alpha. He has served as scientific director for clinical research in the Center for Cancer Research at the NIH until 2016. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He  is a past member of the Board of Governors of the Clinical Center at NIH. In addition to his many appointments with different organization, he has been appointed director of the Osteosarcoma Institute